Breaking News Nov 16, 2026 · 1 min read

Eli Lilly to acquire Calytrix Bio for up to $1.5B

Eli Lilly has agreed to acquire Calytrix Bio, a privately held, JPMorgan-backed company developing therapies for rare blood cancers, for up to $1.5 billion, per the Wall Street Journal. The deal adds oncology assets to Lilly's pipeline as it continues to diversify beyond metabolic drugs. The price tag of up to $1.5B signals Lilly's willingness to pay up for early-stage oncology science.

Source:
Wsj: https://www.wsj.com/business/deals/eli-lilly-to-buy-calytrix-bio-for-up-to-1-5-billion-591745e4

Not financial advice. For informational and educational purposes only.

Track your live portfolio alongside our daily institutional research

Connect your brokerage in 60 seconds and get full access to Position Tracker Substack research inside your dashboard.

Start your free trial →